Showing 4681-4690 of 5646 results for "".
- Bausch + Lomb Highlights Surgical, Pharmaceuticals and Consumer Health Care Innovations at AAO 2020 Virtual Meetinghttps://modernod.com/news/bausch-lomb-highlights-surgical-pharmaceuticals-and-consumer-health-care-innovations-at-aao-2020-virtual-meeting/2478521/Bausch + Lomb announced plans to highlight its latest surgical, pharmaceuticals and consumer health care innovations, as well as several new business ventures, at the company’s virtual exhibit booth during the annual meeting of the American Academy of Ophthalmology (AAO), which takes place Nov. 1
- I-MED Pharma Launches Tearcheck Dry Eye Analysis in Canadahttps://modernod.com/news/i-med-pharma-launches-tearcheck-dry-eye-analysis-in-canada/2478522/I-MED Pharma announced the Canadian launch of tearcheck, a diagnostic and analyzing tool that performs 9 exams in under 10 minutes. The tearcheck was designed and developed by the French manufacturer E-Swin and offers the newest technological advancements to simplify dry eye d
- Lensar to Present Several Papers at 2020 AAO Virtual Meetinghttps://modernod.com/news/lensar-to-presents-several-papers-at-2020-aao-virtual-meeting/2478513/Lensar announced the following posters/papers were accepted to be presented at the 2020 AAO Virtual Meeting taking place Nov. 13-15. 2020 AAO Accepted Posters/Papers Company Ty
- Regenxbio Announces Presentations at the American Academy of Ophthalmology 2020 Annual Meetinghttps://modernod.com/news/regenxbio-announces-presentations-at-the-american-academy-of-ophthalmology-2020-annual-meeting/2478516/Regenxbio announced that two oral presentations will be presented at the American Academy Ophthalmology (AAO) 2020 Annual Meeting, taking place November 13-15, 2020 in a virtual format. The first presentation will feature data from the RGX-314 phase 1/2 subret
- Allergan to Share New Data at American Academy of Ophthalmology (AAO) 2020 Virtual Meetinghttps://modernod.com/news/allergan-to-share-new-data-at-american-academy-of-ophthalmology-aao-2020-virtual-meeting/2478510/Allergan, which is now part of AbbVie, announced that it will present new data advancing scientific understanding of an IOP-lowering treatment in glaucoma and evaluating an investigational treatment for presbyopia at American Academy of Ophthalmology (AAO) 2020 virtual meeting (November 13-15).</
- AAO Data: Experimental RNA Based Drug Addresses the Underlying Cause of Rare Eye Diseasehttps://modernod.com/news/aao-data-experimental-rna-based-drug-addresses-the-underlying-cause-of-rare-eye-disease/2478509/At the virtual AAO 2020 meeting, ProQR Therapeutics will present two posters on its lead product candidate sepofarsen for the treatment of the root cause of Leber congenital amaurosis 10 (LCA10), a rare eye disease that damages the development of the retina and causes severe vision loss. P
- New Alcon Innovations in IOLs, Digital Health Solutions to be Showcased at the AAO 2020 Virtual Annual Meetinghttps://modernod.com/news/new-alcon-innovations-in-iols-digital-health-solutions-to-be-showcased-at-the-aao-2020-virtual-annual-meeting/2478506/Alcon will highlight a robust scientific program including new data and advancements across its portfolio of innovations in cataract, refractive and retina surgery during the American Academy of Ophthalmology (AAO) 2020 virtual annual meeting, which takes place November 13-15, 2020, according to
- Oxurion NV Confirms New Patents for THR-687 Issued by European and US Patent Officeshttps://modernod.com/news/oxurion-nv-confirms-new-patents-for-thr-687-issued-by-european-and-us-patent-offices/2478504/Oxurion NV announced a strengthening of its intellectual property (IP) portfolio governing THR-687, an integrin antagonist being developed for the treatment of DME. The European Patent Office (EPO) and the United States Patent and Trademark Office (USPTO) have both issued new composition-o
- COVID-19 Vaccine Safety Efforts to Feature App Tracking of Vulnerable Groupshttps://modernod.com/news/covid-19-vaccine-safety-efforts-to-feature-app-tracking-of-vulnerable-groups/2478501/Government health officials and drugmakers plan to roll out extra tools to detect whether COVID-19 vaccines cause any serious side effects once the shots are cleared for widespread use, aiming to fill gaps in existing safeguards given the expected speed and scope of
- First COVID-19 Vaccine Doses To Go To Health Workers, Say CDC Advisershttps://modernod.com/news/first-covid-19-vaccine-doses-to-go-to-health-workers-say-cdc-advisers/2478502/Health care workers will almost certainly get the first doses of COVID-19 vaccine in the U.S. when one is approved, according to Dr. José Romero, head of the committee that develops evidence-based immunization guidelines for the Centers for Disease Control and Prevention, as